Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Glutamate ionotropic receptor NMDA type subunit 2C (GRIN2C) is a fundamental component of the N-methyl-D-aspartate (NMDA) receptor complex, which functions as a heterotetrameric, ligand-gated ion channel in the central nervous system (UniProt: Q14957). This subunit is uniquely characterized by its high expression levels in the cerebellum, particularly within the granule cells, where it contributes to the modulation of excitatory neurotransmission and synaptic plasticity (PubMed: 25339738). Biophysically, receptors containing the GRIN2C subunit exhibit distinct properties, including a reduced sensitivity to magnesium-dependent block and lower single-channel conductance compared to those containing 2A or 2B subunits (NCBI Gene: 2905). These characteristics allow GRIN2C to play a specialized role in maintaining tonic NMDA receptor activity and supporting long-term depression (LTD) in cerebellar circuits.\n\nIn the context of human health, genetic variations and altered expression of GRIN2C have been associated with several neuropsychiatric conditions, most notably schizophrenia and bipolar disorder (PubMed: 15505651). The subunit is also implicated in neurodevelopmental disorders and may play a role in the pathophysiology of Parkinson's disease. Pharmacologically, while many traditional NMDA receptor antagonists like ketamine and memantine are non-selective, there is significant research into developing subunit-selective modulators (PubMed: 20810946). Selective negative allosteric modulators (NAMs) and positive allosteric modulators (PAMs) targeting GRIN2C are being explored for their potential to treat cognitive deficits and motor dysfunction while avoiding the broad side effects associated with global NMDA receptor inhibition.
Non-competitive antagonism, Positive allosteric modulation, and Negative allosteric modulation of the NMDA receptor complex (PubMed: 20810946).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glutamate ionotropic receptor NMDA type subunit 2C (GRIN2C) (GRIN2C).